Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15540674 | 0.83 | PTGS2 (0.50) | MAPTLMNACYP2C9CYP2C19KDM4E | |
| SCHEMBL17645209 | 0.82 | AR (0.45) | POLBALDH1A1MCL1RECQLP2RX3 | |
| SCHEMBL17987851 | 0.81 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17645416 | 0.80 | MCL1 (0.40) | MAPTLMNAPOLBKDM4EALDH1A1 | |
| SCHEMBL25248872 | 0.80 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22639174 | 0.78 | PPARG (0.33) | MAPTLMNAPOLBALDH1A1P2RX3 | |
| SCHEMBL30225325 | 0.78 | CA12 (0.55) | CYP2C19ATR | |
| SCHEMBL17687915 | 0.78 | CA12 (0.55) | CYP2C19ATR | |
| SCHEMBL17024452 | 0.78 | LMNA (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14484808 | 0.78 | MCL1 (0.54) | MAPTLMNAALDH1A1KMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-10 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-01-04 | — | — | US | disclosed |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2016123253-A1 | HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123253-A1 | HYDRAZNE DERIVATIVES FOR THE TREATMENT OF CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-04 | — | — | WO | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
| US-20180000806-A1 | HYDRAZONE DERIVATIVES FOR THE TREATMENT OF CANCER | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PSEN1 4654/4885PSEN2 4755/4885APH1B 4448/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
| US-10828288-B2 | Hydrazone derivatives for the treatment of cancer | H1-3, H1-5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PSEN1 4654/4885PSEN2 4755/4885APH1B 4448/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PSEN1 792/4885PSEN2 1971/4885APH1B 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.